Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
复制标题
DOI：
10.1097/mog.0000000000000171
复制
发表时间：
2015-05
影响因子：
2.5
通讯作者：
Roberts LR
中科院分区：
文献类型：
--
作者：
Borad MJ;Gores GJ;Roberts LR
本文就成纤维细胞生长因子通路在胆管癌发病机制中的作用、靶向治疗的可能性及预后价值作一综述。最近的研究已经确定了成纤维细胞生长因子受体2（FGFR2）融合，FGFR2融合的预后影响，治疗策略，目标FGFR2在CCA和未来的方向，了解和针对FGFR2途径在这种疾病，将进行讨论。了解FGFR2途径作为疾病发病机制的作用以及围绕这一概念开发靶向治疗和诊断的能力是开发CCA新靶向方法的关键要素。
This review will cover the role of the fibroblast growth factor pathway in the pathogenesis, targeted therapy potential and prognostic value in patients with cholangiocarcinoma (CCA). Recent studies that have identified fibroblast growth factor receptor 2 (FGFR2) fusions, prognostic implications of FGFR2 fusions, treatment strategies that target FGFR2 in CCA and future directions for understanding and targeting the FGFR2 pathway in this disease, will be discussed. Understanding the role of the FGFR2 pathway as a disease pathogenetic mechanism and the ability to develop targeted therapies and diagnostics surrounding this concept are critical elements toward developing novel targeted approaches in CCA.